Walgreen Growing Kaleo Partnership Amid National Shortage Of Allergy Shots
Walgreen Boots Alliance (WBA), a recent addition to the Dow 30, is a pharmacy-led, health and wellbeing enterprise with a long history of trusted healthcare services, community pharmacy care, and pharmaceutical wholesaling dates.
Last week, Walgreens Boots Alliance Inc announced that it is expanding its partnership with Kaleo Inc. to introduce its epinephrine auto-injectors in addition to existing Kaleo’s Auvi-Q shots in pharmacies for infants and toddlers to meet national shortage of allergy shots in an emergency. Reportedly recently, Novartis AG also announced to provide epinephrine shots for immediate use in local pharmacies across the United States.
Mylan NV, the maker EpiPen is the market leader for treating severe allergies. High-Demand for these devices in summer coupled with manufacturing delays via Pfizer (PFE) the sole producer of all EpiPens has led to a severe shortage of shots. Pfizer is reported that it expects further supply shortages of the EpiPen in coming months. This has landed EpiPen on the U.S. Food and Drug Administration’s list of drugs for shortages over a year.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Join us at Vista Partners!